Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 11/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 8/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225496 | 0.87 | CRHBP (0.54) | ABCB1ABCC1KCNMA1CRHBPCRHR2 | |
| SCHEMBL6224259 | 0.79 | SMN1; SMN2 (0.47) | ABCB1ACLYCRHBPCRHR2ALDH1A1 | |
| SCHEMBL6225781 | 0.77 | ABCB1 (0.46) | ABCB1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL6224090 | 0.77 | HSPB1 (0.47) | ABCB1ABCC1CRHBPCRHR2ALDH1A1 | |
| SCHEMBL6226629 | 0.76 | MAPT (0.43) | ABCB1MAPT | |
| SCHEMBL4942593 | 0.75 | PDCD1 (0.38) | ABCB1CRHBPCRHR2ALDH1A1MAPT | |
| SCHEMBL4942600 | 0.75 | PDCD1 (0.38) | ABCB1CRHBPCRHR2ALDH1A1MAPT | |
| SCHEMBL6225897 | 0.75 | ABCB1 (0.50) | ABCB1ABCC1ALDH1A1MAPTNPC1 | |
| SCHEMBL27502700 | 0.74 | ABCB1 (0.53) | ABCB1ABCC1KCNMA1CRHBPCRHR2 | |
| SCHEMBL6225602 | 0.74 | ABCB1 (0.50) | ABCB1ABCC1ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | ABCB1 176/4885ABCC1 287/4885KCNMA1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.